CG Oncology, Inc. Operating Lease Cost
CG Oncology, Inc. (CGON) reported Operating Lease Cost of $410.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- CG Oncology, Inc. operating lease, cost for the quarter ending 2026-06-30 was $410.00K, a 376.74% increase year-over-year.
- CG Oncology, Inc. operating lease, cost for the quarter ending 2026-03-31 was $338.00K, a 404.48% increase year-over-year.
- CG Oncology, Inc. operating lease, cost for the quarter ending 2025-12-31 was $315.00K, a 472.73% increase year-over-year.
- CG Oncology, Inc. operating lease, cost for the quarter ending 2025-09-30 was $377.00K, a 389.61% increase year-over-year.
- CG Oncology, Inc. operating lease, cost for fiscal 2025 was $699.00K, a 206.58% increase from fiscal 2024.
- CG Oncology, Inc. operating lease, cost for fiscal 2024 was $228.00K, a 1.72% decline from fiscal 2023.
- CG Oncology, Inc. operating lease, cost for fiscal 2023 was $232.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $410.00K 10-Q · filed 2026-08-06 | $747.00K 10-Q · filed 2026-08-06 | $1.06M derived: sum of 3 quarters · filed 2026-08-06 | $1.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $338.00K 10-Q · filed 2026-05-08 | $653.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.03M derived: sum of 3 quarters · filed 2026-05-08 | $1.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $692.00K derived: sum of 2 quarters · filed 2026-02-27 | $778.00K derived: sum of 3 quarters · filed 2026-08-06 | $699.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $377.00K 10-Q · filed 2025-11-14 | $463.00K derived: sum of 2 quarters · filed 2026-08-06 | $384.00K 10-Q · filed 2025-11-14 | $585.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $86.00K 10-Q · filed 2026-08-06 | $152.00K 10-Q · filed 2026-08-06 | $208.00K derived: sum of 3 quarters · filed 2026-08-06 | $285.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $67.00K 10-Q · filed 2026-05-08 | $122.00K derived: sum of 2 quarters · filed 2026-05-08 | $199.00K derived: sum of 3 quarters · filed 2026-05-08 | $234.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $132.00K derived: sum of 2 quarters · filed 2026-02-27 | $167.00K derived: sum of 3 quarters · filed 2026-02-27 | $228.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $77.00K 10-Q · filed 2025-11-14 | $112.00K derived: sum of 2 quarters · filed 2025-11-14 | $173.00K 10-Q · filed 2025-11-14 | $226.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $35.00K 10-Q · filed 2025-08-08 | $96.00K 10-Q · filed 2025-08-08 | $149.00K derived: sum of 3 quarters · filed 2025-08-08 | $206.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $61.00K 10-Q · filed 2025-05-13 | $114.00K derived: sum of 2 quarters · filed 2025-05-13 | $171.00K derived: sum of 3 quarters · filed 2025-05-13 | $231.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $110.00K derived: sum of 2 quarters · filed 2025-03-28 | $170.00K derived: sum of 3 quarters · filed 2025-03-28 | $232.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $57.00K 10-Q · filed 2024-11-12 | $117.00K derived: sum of 2 quarters · filed 2024-11-12 | $179.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $60.00K 10-Q · filed 2024-08-08 | $121.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $57.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |